

# Marcello Deraco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9359420/publications.pdf>

Version: 2024-02-01

17  
papers

682  
citations

840776

11  
h-index

940533

16  
g-index

20  
all docs

20  
docs citations

20  
times ranked

661  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1590-1597.	1.0	6
2	Diagnostic and therapeutic algorithm for colorectal peritoneal metastases. A consensus of the peritoneal surface malignancies onco-team of the Italian society of surgical oncology. <i>European Journal of Surgical Oncology</i> , 2021, 47, 164-171.	1.0	2
3	Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2021, 47, 1132-1139.	1.0	12
4	Fertility preservation in women with peritoneal surface malignancies: A case series. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2948-2951.	1.0	2
5	The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI). <i>European Journal of Surgical Oncology</i> , 2021, 47, 2888-2892.	1.0	26
6	Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS). <i>Annals of Surgical Oncology</i> , 2020, 27, 98-106.	1.5	26
7	Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases From a Small Bowel Adenocarcinoma: Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 1184-1192.	1.5	30
8	Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 404-413.	1.5	61
9	Learning Curve, Training Program, and Monitorization of Surgical Performance of Peritoneal Surface Malignancies Centers. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 507-517.	1.5	27
10	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial. <i>Gynecologic Oncology</i> , 2011, 122, 215-220.	1.4	131
11	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Patient with Peritoneal Mesothelioma and HIV Infection. <i>Tumori</i> , 2010, 96, 340-344.	1.1	3
12	Experience with peritoneal mesothelioma at the Milan National Cancer Institute. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 76.	2.0	22
13	Consensus statement on peritoneal mesothelioma. <i>Journal of Surgical Oncology</i> , 2008, 98, 268-272.	1.7	92
14	Advances in Clinical Research and Management of Diffuse Peritoneal Mesothelioma. , 2007, 169, 137-155.		3
15	Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2006, 13, 229-237.	1.5	144
16	Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center. <i>In Vivo</i> , 2006, 20, 773-6.	1.3	12
17	Cytoreductive Surgery Followed by Intraperitoneal Hyperthermic Perfusion in the Treatment of Recurrent Epithelial Ovarian Cancer: A Phase II Clinical Study. <i>Tumori</i> , 2001, 87, 120-126.	1.1	77